Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Sandler

Showing results (771-780 of 870) with videos related to

Pageof 87
Sort By:
International Journal of Radiation Oncology, Biology, Physics|August 15, 2024
Long-Term Results of Bladder Preservation With Twice-Daily Radiation Plus 5-Fluorouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer-Updated Report of NRG/RTOG 0712: A Randomized Phase 2 TrialJohn J Coen, Joseph P Rodgers, Philip J Saylor, et al.
The Journal of Urology|January 15, 2018
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care OptionsMartin G Sanda, Jeffrey A Cadeddu, Erin Kirkby, et al.
The Journal of Urology|December 6, 2017
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care OptionsMartin G Sanda, Jeffrey A Cadeddu, Erin Kirkby, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2018
Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II TrialJohn J Coen, Peixin Zhang, Philip J Saylor, et al.
International Journal of Radiation Oncology, Biology, Physics|February 8, 2000
Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406J M Michalski, J A Purdy, K Winter, et al.
Cancer|February 26, 2013
Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancerPhillip J Gray, Jonathan J Paly, Beow Y Yeap, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2017
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate CancerWanling Xie, Meredith M Regan, Marc Buyse, et al.
Neurobiology of Disease|December 15, 2019
Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson's diseaseMichael X Henderson, Dustin J Covell, Charlotte Hiu-Yan Chung, et al.
Cancer|January 3, 2014
Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancerBradford S Hoppe, Jeff M Michalski, Nancy P Mendenhall, et al.
Cloning and Stem Cells|February 4, 2009
Reprogramming of human somatic cells using human and animal oocytesYoung Chung, Colin E Bishop, Nathan R Treff, et al.
Pageof 87

Showing results (771-780 of 870) with videos related to

Sort By:
Pageof 87
International Journal of Radiation Oncology, Biology, Physics|August 15, 2024
Long-Term Results of Bladder Preservation With Twice-Daily Radiation Plus 5-Fluorouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer-Updated Report of NRG/RTOG 0712: A Randomized Phase 2 TrialJohn J Coen, Joseph P Rodgers, Philip J Saylor, et al.
The Journal of Urology|January 15, 2018
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care OptionsMartin G Sanda, Jeffrey A Cadeddu, Erin Kirkby, et al.
The Journal of Urology|December 6, 2017
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care OptionsMartin G Sanda, Jeffrey A Cadeddu, Erin Kirkby, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2018
Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II TrialJohn J Coen, Peixin Zhang, Philip J Saylor, et al.
International Journal of Radiation Oncology, Biology, Physics|February 8, 2000
Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406J M Michalski, J A Purdy, K Winter, et al.
Cancer|February 26, 2013
Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancerPhillip J Gray, Jonathan J Paly, Beow Y Yeap, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2017
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate CancerWanling Xie, Meredith M Regan, Marc Buyse, et al.
Neurobiology of Disease|December 15, 2019
Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson's diseaseMichael X Henderson, Dustin J Covell, Charlotte Hiu-Yan Chung, et al.
Cancer|January 3, 2014
Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancerBradford S Hoppe, Jeff M Michalski, Nancy P Mendenhall, et al.
Cloning and Stem Cells|February 4, 2009
Reprogramming of human somatic cells using human and animal oocytesYoung Chung, Colin E Bishop, Nathan R Treff, et al.
Pageof 87